`
`Calderari, et al.
`
`Serial No.:
`
`11/186,311
`
`Filing Date:
`
`July 21, 2005
`
`)
`
`Title: LIQUID PHARMACEUTICAL
`FORMULATIONS OF
`PALONOSETRON
`
`)
`)
`)
`)
`)
`)
`
`)
`)
`)
`)
`
`Art Unit: 1614
`
`Examiner: Gembeh, Shirley V.
`
`STATUTORY DECLARATION OF DANIELE BONADEO, M. Chem. Pharm.
`37 C.F.R. §§ 131 and 132
`
`Commissioner for Patents
`P .0. Box 1450
`Alexandria, VA 22313-1450
`
`3)
`
`I, Daniele Bonadeo, hereby give this declaration under 37 C.F.R. §§ 131 and 132:
`1)
`My name is Daniele Bonadeo.
`I make this declaration based on my own personal knowledge, information, and belief. I
`2)
`am competent to testify concerning the matters set forth herein.
`I am Deputy Director, Head of Corporate Technical Affairs, Manufacturing Operations,
`for Helsinn Healthcare SA ("Helsinn"), the assignee of the above-referenced patent
`application.
`I am also an inventor for this application.
`This patent application is based on the discovery of liquid formulations of palonosetron
`hydrochloride with improved stability. The formulations can be stored for prolonged
`
`4)
`5)
`
`I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail
`addressed to: Commissioner for Patents, P. 0. Box 1450, Alexandria, VA 22313-1450, on February 1-C., 200'~
`
`Clark G. Sullivan, Reg. No. 36,942
`
`Dr. Reddy’s Laboratories, Ltd., et al.
`v.
`Helsinn Healthcare S.A., et al.
`U.S. Patent No. 9,(cid:20)(cid:26)(cid:22),(cid:28)(cid:23)(cid:21)
`Reddy Exhibit 1054
`
`Exh. 1054
`
`
`
`Serial No. 11/186,311
`Declaration ofDaniele Bonadeo
`Page2 of4
`
`periods of time in a variety of conditions without significant degradation or loss of
`potency, and thus are considered pharmaceutically stable.
`The formulations were developed by myself and others at Helsinn in the late 1990s, and
`were completed sometime before March 24, 1999.
`We filed U.S.S.N. 60/444,351, which was our first patent application based on these
`formulations, on January 30, 2003. We filed PCT application No. PCT/EP04/000888 on
`January 30, 2004, claiming priority to the '351 application. We filed U.S.S.N.
`11/186,311 on July 21,2005, claiming priority to the US '351 and PCT '888 applications.
`Finally, we filed three continuation applications -- U.S.S.N. 11/388,268 (the '268
`application), U.S.S.N. 111388,269 (the '269 application), and U.S.S.N. 11/388,270 (the
`'270 application), on March 4, 2006, claiming priority to the US '311 application, the US
`'351 application, and the PCT '888 application.
`Each of the foregoing applications contains the following example of an injectable
`formulation of palonosetron hydrochloride:
`
`6)
`
`7)
`
`8)
`
`EXAMPLE 4: FORMULATION [
`
`Ingredient
`Palonosetron Hydrochloride
`Mannitol
`EDTA
`Trisodium citrate
`Citric acid
`WFJ
`hydroxide
`solution
`Sodium
`hydrochloric acid solution
`
`and/or
`
`me/mL
`0.05
`41.5
`0.5
`3.7
`1.56
`1.0
`pH5.0±0.5
`
`9)
`1 0)
`
`For ease of reference, I will refer to this formulation as the Example 4 formulation.
`The Example 4 formulation was developed sometime before March 24, 1999, by myself
`and others at Helsinn Healthcare, and transmitted to a contract manufacturer for Helsinn,
`Oread Laboratories in Palo Alto California ("Oread"), for the production of commercial
`scale batches of palonosetron hydrochloride.
`
`Exh. 1054
`
`
`
`Serial No. 11/186,311
`Declaration ofDaniele Bonadeo
`Page 3 of4
`
`11)
`
`12)
`
`13)
`
`14)
`
`15)
`
`16)
`
`1 7)
`
`A copy of the master batch record developed by Oread for the formulation is contained in
`Exhibit A hereto.
`The master batch record describes the Example 4 formulation on page 2 of22. As can be
`seen, the batch record has an effective date of March 24, 1999, and thus makes clear that
`we had developed the formulation before this date.
`I am familiar with the work of Macciocchi et al. that is described in WO 2004/045615
`(the "Macciocchi application"), and the work of Baroni et al. that is described in WO
`2004/073714 (the "Baroni application"). With the exception of Dr. Macciocchi, who
`recently passed away, the inventors for those patent applications are close colleagues of
`mine who also work at Helsinn or, in the case of Dr. Baroni, recently retired from
`Helsinn.
`The Macciocchi and Baroni PCT applications were filed on November 6, 2003 and
`February 18, 2004, respectively, which is more than four years after we first invented the
`Example 4 formulation.
`At least some of the clinical studies described in the Macciocchi and Baroni applications
`used the Example 4 formulation.
`Any description in the Macciocchi and Baroni applications of palonosetron formulations
`having a pH between 4 and 6, palonosetron concentrations between 0.01 and 5.0 mg/ml,
`or the use of mannitol or a chelating agent in liquid palonosetron formulations, was
`derived from the Example 4 formulation that we presented to Drs. Macciocchi and Baroni
`for use by them in their clinical programs.
`All of the formulation development work described in the foregoing paragraphs was
`performed in Switzerland, which to my knowledge has been a member of the World
`Trade Organization (WTO) since July 1, 1995, and the United States.
`
`I declare that all statements made herein of my own knowledge are true and that all
`statements made on information and belief are believed to be true, further, that these statements
`were made with the knowledge that willful false statements and the like so made are punishable
`
`Exh. 1054
`
`
`
`by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code. I
`declare under penalty of perjury that the foregoing is true and correct.
`
`Serial No. 111186,311
`Declaration ofDaniele Bonadeo
`Page4 of4
`
`Dated: February 13, 2007
`
`Daniele Bonadeo
`
`Exh. 1054
`
`
`
`~f""
`
`; ;.~·
`
`®
`
`/) "
`'
`.
`
`I
`
`"
`•
`:•
`
`~
`
`Onlad, f'alo Alla, CA
`
`Product: PalonosellOn HCIIntiiVCII'ICXIB
`lnJec:Uon, 0.05 mdmL. &Me
`
`Fomwlllfan No.: I PID No •. : 75941 MBR No.: D't7B001.00
`8UUC BTS\ILE SCll.UTIOH
`~ Pag&fat~
`Lot Ha.: 1 7 3 7 3-2_1 ___ . -·
`
`FD77A-oo9
`CUent FlD Ha.: N/A
`
`241999
`
`Sucaenedn: OdoiNII
`
`llT }
`.1' • tr ,,
`-r
`)>
`
`ElfiiC'IIII'I Dill:
`sc.ae:
`:so Litert
`Muw RIICORI Approwls
`E. .JJnb•~
`PriQIIredot
`
`fam'llllllon DIMitlpmanl
`
`::e 1-dzk, £~
`
`=:;ltr/?1
`• Dale
`a-tz-t:tf
`Date
`
`Slelia
`
`"'~·
`~ ,
`~~~~
`18'117"1"'11
`Dale :·
`
`I"IIJ
`
`/to,th Zi, 'ff
`
`-~
`
`ThiONCir:al Lot.Size:
`
`30
`. Lllen
`s• ~ 5.3
`
`11LIVIal
`
`Client Lot No.;
`
`NIA
`
`Dale Filltollol'l C4Dple1ed:
`Mltnufactutlng ~e:
`
`. _
`
`Dille eompollftdk1Q Slatled: ·---r:s,-. .,.,--- -
`~ 'JJ· 99
`--"'!""'"" ~ ..... ..-.
`PaJo Alo, CA
`~~Iff/
`Dale 1
`fh'b l~l(HLii1u!fY
`l·51·~V~';r,
`I\ c
`SWtlo
`Dale
`.
`__lj_~J;?L-:--".
`Cwnplaled Ba!.Ch Ret10rd RovilwedBy. - - - - • \ ~~...::;.l...,j}1~NA~w..l\~ .. - - - - - - - - - - -
`
`~lelad BalCh Aecold Rewland Br.
`
`PIIUI01Not0~1JIIOOIIIG0.411c
`
`COHfiOWI'fiN.
`
`BEST AVAILABLE co~: ..
`
`' .
`MASiER
`
`Exh. 1054
`
`
`
`~~
`
`.......... \
`)
`t
`
`@
`
`~
`f ·}.
`
`Oread, Palo Alto, CA
`
`Product: Palonosetron HCI Intravenous
`Injection, 0.05 mglmL. Bulk
`
`·-········--·--
`
`Formulation No.:
`FDnA-oo9
`Client FID No.: N/A
`
`PID No.: 75941
`
`MBR No.: 0778001.00
`LotNo.: 1
`
`BULK STERILE SOlJJTlOH
`Page2 of22
`
`BILL OF MATERIALS
`c::.n.m11: ft.at::a• , :rnw. raar
`~ Uh 7Stu ~ • rD DCII!I
`1111t ~ , N::tlVB
`-~~ HCL IR'l"RAVDIOOS :nr.:nt:TIQf, 0.05 IG/ICL,IULI:, PD71A•OO!t 1D'I7A1
`
`OD
`
`t 18-PII•l"!t
`
`.,_.CII'ip~oatCLIM, BSSIIII'!,'V.LLY COLOJU.BSS SOLII"l''ctl
`ltGnfia ~I:IIJ
`IIOCal "lap
`trot.ct. f1:011 licmt.
`
`2a
`
`:sa
`
`'0
`
`50
`
`ll'ol:lllllAtt• DIMJJ.• t
`!!!.:.!!!:. %1qw4i•t.
`10 um • ~~~Hanu-t" (.IIC'rlVI sua)
`c.-ata I
`IODlVII c:l'l'U'llt. D~Rn~~~A'IZ, vn ca:Inlll'l')
`sm -
`c-lUI
`sscs - cr.nu:c .acm, IPIIIIMlRA'l'l, C~W~ULAR, IJSl' (m:ln&l.ft')
`c.-ato• I
`)011 • IZlm.TI DISICIDXVH, USP (CIIIZN) DfV] IBXCIPUII'l')
`c-ltl I
`:S211 • JINI1U'I'OL,
`c-lbt
`
`IJSP (II.CUZI:tl'l')
`
`10
`
`'0
`
`ao
`
`o-tat
`21:1•1 • 1lC IIOOlVII ~ 150W'!'XCII, Pltl!PAIIED Cfti 111'1 (PCIRII XICil)
`(It 'l'o I q,l, W pfl $,0 +/• 0,$
`c.-ata I
`:I.C171 - Mllll'A roa D.1IDCl'l'IQf. VSP 1 EXX:X Pl1!H'I'I
`c-a-..
`QS 'l'o I q.l, to 1.0 IlL
`
`P lllMIOTI'IMBR 'S'ID77B001100.110c
`
`Qj::~1" ,1.\,VAILABLE COPY
`
`CONADENTIAL
`
`l\llll..satita Quat:i~t
`
`.......
`
`USJI
`
`tiSP
`
`OSP
`
`. USP
`
`liP
`
`)II'
`
`US II'
`
`:liiL
`
`CIMD!!!!;
`.os IICJ
`
`,,, IICJ
`
`l.SC 110'
`
`.S 11G
`
`u.s 110
`
`0
`
`0
`
`0
`
`'•
`• J
`I j
`MASTER
`
`i
`
`Exh. 1054